248 related articles for article (PubMed ID: 27989877)
1. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression.
Li L; Wang S; Zheng F; Wu W; Hann SS
J Ethnopharmacol; 2016 Dec; 194():918-929. PubMed ID: 27989877
[TBL] [Abstract][Full Text] [Related]
2. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
3. Decoction of Chinese Herbal Medicine Fuzheng Kang-Ai Induces Lung Cancer Cell Apoptosis via STAT3/Bcl-2/Caspase-3 Pathway.
Wang S; Long S; Xiao S; Wu W; Hann SS
Evid Based Complement Alternat Med; 2018; 2018():8567905. PubMed ID: 30046347
[TBL] [Abstract][Full Text] [Related]
4. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
5. Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway.
Wang S; Peng Z; Li W; Long S; Xiao S; Wu W
Cancer Cell Int; 2020; 20():185. PubMed ID: 32489321
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression.
Wu J; Tang Q; Ren X; Zheng F; He C; Chai X; Li L; Hann SS
J Ethnopharmacol; 2019 Jun; 237():128-140. PubMed ID: 30910577
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of PI3-K/Akt and reduction of SP1 and p65 expression increase the effect of solamargine on suppressing EP4 expression in human lung cancer cells.
Chen Y; Tang Q; Wu J; Zheng F; Yang L; Hann SS
J Exp Clin Cancer Res; 2015 Dec; 34():154. PubMed ID: 26689593
[TBL] [Abstract][Full Text] [Related]
8. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
10. Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPKα-Mediated Induction and Interplay of IGFBP1 and FOXO3a.
Zheng F; Wu J; Li X; Tang Q; Yang L; Yang X; Wu W; Hann SS
Evid Based Complement Alternat Med; 2016; 2016():5060757. PubMed ID: 27057199
[TBL] [Abstract][Full Text] [Related]
11. Chinese herbal medicine Xiaoji decoction inhibited growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1.
Zhao S; Wu J; Tang Q; Zheng F; Yang L; Chen Y; Li L; Hann SS
J Ethnopharmacol; 2016 Apr; 181():172-81. PubMed ID: 26850724
[TBL] [Abstract][Full Text] [Related]
12. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
13. Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway.
Tang Q; Wang X; Zhou Q; Li Q; Yang X; Xu M; Wang R; Chen J; Wu W; Wang S
Phytomedicine; 2023 Jun; 114():154819. PubMed ID: 37062135
[TBL] [Abstract][Full Text] [Related]
14. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
[TBL] [Abstract][Full Text] [Related]
17. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
18. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
